Portal de Periódicos da CAPES

A Prospective, 1-Year Trial Using Saw Palmetto Versus Finasteride in the Treatment of Category III Prostatitis/Chronic Pelvic Pain Syndrome

2004; Lippincott Williams & Wilkins; Volume: 171; Issue: 1 Linguagem: Inglês

10.1097/01.ju.0000101487.83730.80

1527-3792

Steven A. Kaplan, Michael Volpe, Alexis E. Te,

Pelvic floor disorders treatments

No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Jan 2004A Prospective, 1-Year Trial Using Saw Palmetto Versus Finasteride in the Treatment of Category III Prostatitis/Chronic Pelvic Pain Syndrome STEVEN A. KAPLAN, MICHAEL A. VOLPE, and ALEXIS E. TE STEVEN A. KAPLANSTEVEN A. KAPLAN , MICHAEL A. VOLPEMICHAEL A. VOLPE , and ALEXIS E. TEALEXIS E. TE View All Author Informationhttps://doi.org/10.1097/01.ju.0000101487.83730.80AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: This study was designed to assess the safety and efficacy of saw palmetto or finasteride in men with category III prostatitis/chronic pelvic pain syndrome (CP/CPPS). Materials and Methods: A prospective, randomized, open label, 1-year study was designed to assess the safety and efficacy of saw palmetto and finasteride in the treatment of men diagnosed with CP/CPPS. Patients were randomized to finasteride (5 mg once daily) or saw palmetto (325 mg daily) for 1 year. Patients were evaluated using the National Institutes of Health Chronic Prostatitis Symptom Index, individual domains (pain, urinary symptoms, quality of life and mean pain score) and the American Urological Association Symptom Score at baseline, 3, 6 and 12 months. Results: A total of 64 consecutive men 24 to 58 years old (mean age 43.2) with a diagnosis of CP/CPPS were equally randomized to the 2 treatment arms. All 64 men had previously received antibiotics (duration of 3 to 93 weeks), 52 (82%) had been on α-blockade. There were 61, 57 and 56 patients evaluable at 3, 6 and 12 months, respectively. At 1 year mean total National Institutes of Health Chronic Prostatitis Symptom Index score decreased from 23.9 to 18.1 in the finasteride group (p <0.003), and from 24.7 to 24.6 in the saw palmetto arm (p = 0.41). In the finasteride arm the quality of life and pain domains were significantly improved at 1 year; however, urination was not. Adverse events included headache (3 cases) in the saw palmetto group and decreased libido (2 cases) in the finasteride group. At the end of the trial 13 of 32 (41%) and 21 of 32 (66%) opted to continue saw palmetto and finasteride, respectively. Conclusions: CP/CPPS treated with saw palmetto had no appreciable long-term improvement. In contrast, patients treated with finasteride had significant and durable improvement in all various parameters except voiding. Further studies are warranted to ascertain the mechanism and reproducibility of these effects in a placebo controlled trial. References 1 : Prostatitis: myths and realities. Urology1998; 51: 362. Google Scholar 2 : How common is prostatitis? A national survey of physician visits. J Urol1998; 159: 1224. Link, Google Scholar 3 : Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index. J Urol2001; 165: 842. Link, Google Scholar 4 : Effective office management of chronic prostatitis. Urol Clin North Am1998; 25: 677. Google Scholar 5 : Phytotherapy and other alternative forms of care for the patient with prostatitis. Curr Urol Rep2002; 3: 330. Google Scholar 6 : Effects of finasteride in patients with inflammatory chronic pelvic pain syndrome: a double-blind, placebo-controlled, pilot study. Urology1999; 53: 502. Google Scholar 7 : Results of treatment with pollen extract (Cernilton N) in chronic prostatitis and prostatodynia. Br J Urol1993; 71: 433. Google Scholar 8 : Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology1999; 54: 960. Google Scholar 9 : Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol2000; 163: 1451. Link, Google Scholar 10 : Effect of lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids1997; 57: 299. Google Scholar 11 : The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med1998; 338: 557. Google Scholar 12 : Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology2002; 59: 870. Google Scholar 13 : Anti-inflammatory properties of plant flavonoids. Effects of rutin, quercetin and hespiridin on adjuvant arthritis in rats. Farmaco2001; 56: 683. Google Scholar 14 : Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging1996; 9: 379. Google Scholar 15 : Effects of sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasia. Prostate1996; 28: 300. Google Scholar 16 : Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA1998; 280: 1604. Google Scholar 17 : Steroid 5 alpha-reductase: two genes/two enzymes. Annu Rev Biochem1994; 63: 25. Google Scholar 18 : Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition. Prostate1993; 22: 43. Google Scholar 19 : Treatment of prostatic bleeding: suppression of angiogenesis by androgen deprivation. J Urol1993; 149: 1553. Link, Google Scholar 20 : Effect of finasteride on microvessel density (MVD) in patients with recurrent haematuria related to prostatic hypertrophy (BPH). J Urol1999; 161: 363. abstract 1406. Google Scholar From the Department of Urology, College of Physicians and Surgeons of Columbia University (SAK, MAV) and the Department of Urology, Weill Medical College, Cornell University (AET), New York, New York© 2004 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byKaplan S (2018) Re: Associations Between Variants in the Cyclooxygenase 2 Enzyme Gene (PTGS2) and Development of Benign Prostate EnlargementJournal of Urology, VOL. 188, NO. 5, (1845-1846), Online publication date: 1-Nov-2012.Nickel J, Roehrborn C, Montorsi F, Wilson T and Rittmaster R (2018) Dutasteride Reduces Prostatitis Symptoms Compared With Placebo in Men Enrolled in the REDUCE StudyJournal of Urology, VOL. 186, NO. 4, (1313-1318), Online publication date: 1-Oct-2011.Kaplan S (2018) Benign Prostatic HyperplasiaJournal of Urology, VOL. 183, NO. 5, (1933-1938), Online publication date: 1-May-2010.Kaplan S (2018) Benign Prostatic HyperplasiaJournal of Urology, VOL. 180, NO. 2, (633-636), Online publication date: 1-Aug-2008.ROWE E, SMITH C, LAVERICK L, ELKABIR J, WITHEROW R and PATEL A (2018) A PROSPECTIVE, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE-BLIND STUDY OF PELVIC ELECTROMAGNETIC THERAPY FOR THE TREATMENT OF CHRONIC PELVIC PAIN SYNDROME WITH 1 YEAR OF FOLLOWUPJournal of Urology, VOL. 173, NO. 6, (2044-2047), Online publication date: 1-Jun-2005. Volume 171Issue 1January 2004Page: 284-288 Advertisement Copyright & Permissions© 2004 by American Urological Association, Inc.KeywordsprostatitisserenoafinasterideMetricsAuthor Information STEVEN A. KAPLAN More articles by this author MICHAEL A. VOLPE More articles by this author ALEXIS E. TE More articles by this author Expand All Advertisement PDF downloadLoading ...